Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response | Zendy

Xianjun Li | Zendy; Yang Liu | Zendy; Ming Shan | Zendy; Bingqi Xu | Zendy; LU Yu-bo | Zendy; Guoqiang Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response

Author(s) -

Xianjun Li,

Yang Liu,

Ming Shan,

Bingqi Xu,

LU Yu-bo,

Guoqiang Zhang

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.01.01

Subject(s) - medicine , chemotherapy , breast cancer , proportional hazards model , stage (stratigraphy) , multivariate analysis , surgery , oncology , log rank test , cancer , survival analysis , gastroenterology , paleontology , biology

Neoadjuvant chemotherapy (NACT), initially used to downstage breast cancer, may achieve pathologic complete response (pCR) in patients with no residual invasive breast or axillary disease (1). An increasing number of indications for NACT have been recently described; in addition to downstaging, NACT may benefit patients with human epidermal growth factor receptor (HER)2positive or triple-negative stage II–III breast cancer and hormone receptor-positive (HR+) patients with an explicit need for chemotherapy (2). NACT did not improve survival in patients with similar baseline characteristics and chemotherapy regimens when compared with adjuvant Original Article

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research